Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

BACKGROUND: We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI). METHODS: This was a post hoc individual patient-level meta-analysis of data from the Phase 3 studies MENSA (M...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Respir Res
Main Authors: Albers, Frank C., Papi, Alberto, Taillé, Camille, Bratton, Daniel J., Bradford, Eric S., Yancey, Steven W., Kwon, Namhee
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2019
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664536/
https://ncbi.nlm.nih.gov/pubmed/31362741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-019-1134-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker